Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/05/2002CA2448639A1 Novel heterocyclic derivatives and medicinal use thereof
12/05/2002CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002CA2448620A1 Vaccination against the feline immunodeficiency virus
12/05/2002CA2448567A1 Modulators of nucleic acid ligands
12/05/2002CA2448528A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
12/05/2002CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002CA2448305A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002CA2448192A1 Pyrimidine derivatives useful as selective cox-2 inhibitors
12/05/2002CA2448160A1 Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
12/05/2002CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002CA2448100A1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002CA2447657A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002CA2447562A1 Pirenzepine ophthalmic gel
12/05/2002CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002CA2446282A1 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
12/05/2002CA2443346A1 Anticholinergic compounds and methods of use
12/05/2002CA2411549A1 Ligands of integrin receptors
12/04/2002EP1262555A1 Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells
12/04/2002EP1262554A2 Defective packaging non-oncoviral vectors based on mpmv and hiv
12/04/2002EP1262543A1 Alpha-amylase activity inhibitors
12/04/2002EP1262197A2 Combination treatment for sleep disorders including sleep apnea
12/04/2002EP1262196A2 Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
12/04/2002EP1262195A1 Vasoactive agents
12/04/2002EP1262194A1 Remedies and preventives for antiphospholipid antibody syndrome
12/04/2002EP1262189A1 Leptin-resistance ameliorating agents
12/04/2002EP1262183A1 Use of norastemizole for the treatment of allergic rhinitis
12/04/2002EP1262181A1 Urease inhibitors
12/04/2002EP1262180A1 Tnf-alpha inhibitors
12/04/2002EP1262179A1 Photodynamic therapy for selectively closing neovasa in eyeground tissue
12/04/2002EP1262175A2 Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
12/04/2002EP1261694A2 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
12/04/2002EP1261638A2 Human fgf-23 gene and gene expression products
12/04/2002EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002EP1261611A2 Inhibitors of hepatitis c virus ns3 protease
12/04/2002EP1261609A1 Triazolotriazinones and the use thereof
12/04/2002EP1261607A1 2,4-disubstituted thiazolyl derivatives
12/04/2002EP1261606A1 Substituted oxazolidinones and their use in the field of blood coagulation
12/04/2002EP1261605A1 Benzoxazole derivatives as tnf and pde iv inhibitors
12/04/2002EP1261602A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors
12/04/2002EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002EP1261600A1 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
12/04/2002EP1261598A1 Internal 1,15-lactones of fluprostenol and related prostaglandin f2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
12/04/2002EP1261595A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
12/04/2002EP1261590A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
12/04/2002EP1261589A1 Imidazole compounds and their use as adenosine deaminase inhibitors
12/04/2002EP1261586A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use
12/04/2002EP1261585A1 Substituted indole mannich bases
12/04/2002EP1261583A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/04/2002EP1261579A1 Dehydroamino acids
12/04/2002EP1261378A2 Biodegradable immunomodulatory formulations and methods for use thereof
12/04/2002EP1261374A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
12/04/2002EP1261372A2 Method of treating cancer with anti-neurotrophin agents
12/04/2002EP1261371A1 Membrane estrogen receptor-directed therapy in breast cancer
12/04/2002EP1261370A1 Therapeutic method for reducing angiogenesis
12/04/2002EP1261369A2 Compositions and methods for tumor-targeted delivery of effector molecules
12/04/2002EP1261367A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
12/04/2002EP1261366A1 Adjuvant treatment by in vivo activation of dendritic cells
12/04/2002EP1261364A1 Method of treating or inhibiting cellular injury or cell death
12/04/2002EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002EP1261362A2 Novel amino acid and peptide inhibitors of staphylococcus virulence
12/04/2002EP1261360A1 Casein derived peptides and uses thereof in therapy
12/04/2002EP1261359A2 An improved herbal composition having antiallergic properties and a process for the preparation thereof
12/04/2002EP1261356A2 Farnesyl protein transferase inhibitor combinations with platinum compounds
12/04/2002EP1261349A1 Compounds with chelation affinity and selectivity for first transition series elements and their use
12/04/2002EP1261348A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
12/04/2002EP1261346A1 Modulation of cardiovascular injury
12/04/2002EP1261343A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
12/04/2002EP1261341A2 Farnesyl protein transferase inhibitor combinations with camptothecin compounds
12/04/2002EP1261337A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
12/04/2002EP1261336A2 Il-8 receptor antagonists
12/04/2002EP1261335A1 Brain, spinal and nerve injury treatment
12/04/2002EP1261332A1 Use of cyp1b1 inhibitors for treating cancer
12/04/2002EP1261331A1 Method and compositions for treating fibrotic diseases
12/04/2002EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002EP1261329A2 Il-8 receptor antagonists
12/04/2002EP1261328A1 Il-8 receptor antagonists
12/04/2002EP1261327A2 Adenosine receptor modulators
12/04/2002EP1261326A1 D-enantiomer of dfmo and methods of use therefor for treating cancer
12/04/2002EP1261323A2 Method of treating gastrointestinal tract disease with purinergic receptor agonists
12/04/2002EP1261322A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
12/04/2002EP1261321A2 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
12/04/2002EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002EP1180026B1 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
12/04/2002EP1131304B1 N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
12/04/2002EP1109529B1 Use of a lipid extract of the skeletonema algae
12/04/2002EP1077967B1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
12/04/2002EP1073417B1 Pharmaceutical aerosol formulation
12/04/2002EP1058683B1 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
12/04/2002EP1001930B1 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
12/04/2002EP0984980B1 20-aralkyl-5alpha-pregnane derivatives
12/04/2002EP0971961B1 N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
12/04/2002EP0928291B1 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
12/04/2002EP0907650B1 N- 4-(heteroarylmethyl)phenyl]-heteroarylamines
1 ... 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 ... 1564